| Literature DB >> 30912167 |
Weixuan Lan1, Xia Xiao1,2,3, Yongjia Jiang1, Lijie Jiang1, Xu Zhao1, Zhaoyang Yu1, Biwen Zhu1, Congcong Li1, Lin Bian1, Zhiqiang Wang1,2,3.
Abstract
Pasteurella multocida is the causative agent of fowl cholera, and florfenicol (FF) has potent antibacterial activity against P. multocida and is widely used in the poultry industry. In this study, we established a P. multocida infection model in ducks and studied the pharmacokinetics of FF in serum and lung tissues after oral administration of 30 mg/kg bodyweight. The maximum concentrations reached (Cmax) were lower in infected ducks (13.88 ± 2.70 μg/ml) vs. healthy control animals (17.86 ± 1.57 μg/ml). In contrast, the mean residence time (MRT: 2.35 ± 0.13 vs. 2.27 ± 0.18 hr) and elimination half-life (T½β : 1.63 ± 0.08 vs. 1.57 ± 0.12 hr) were similar for healthy and diseased animals, respectively. As a result, the area under the concentration curve for 0-12 hr (AUC0-12 hr ) for FF in healthy ducks was significantly greater than that in infected ducks (49.47 ± 5.31 vs. 34.52 ± 8.29 μg hr/ml). The pharmacokinetic differences of FF in lung tissues between the two groups correlated with the serum pharmacokinetic differences. The Cmax and AUC0-12 hr values of lung tissue in healthy ducks were higher than those in diseased ducks. The concentration of FF in lung tissues was approximately 1.2-fold higher than that in serum both in infected and healthy ducks indicating that FF is effective in treating respiratory tract infections in ducks.Entities:
Keywords: zzm321990Pasteurella multocidazzm321990; Pharmacokinetic; ducks; florfenicol; infection
Mesh:
Substances:
Year: 2019 PMID: 30912167 DOI: 10.1111/jvp.12761
Source DB: PubMed Journal: J Vet Pharmacol Ther ISSN: 0140-7783 Impact factor: 1.786